Hansa Biopharma to report Q2 2026 results on July 22
Hansa Biopharma will publish its interim report for January-June 2026 on July 22. The company will host a conference call the same day at 2:00 PM CEST.
Lund, Sweden, July 8, 2026 – Hansa Biopharma announced today it will release its interim financial report for the period January through June 2026 on July 22, 2026. The company will host a quarterly conference call on the same date at 2:00 PM CEST (8:00 AM EDT).
The call will be led by CEO Renée Aguiar-Lucander, CFO Adam Cutler, CMO Richard Philipson, and COO and President U.S. Maria Törnsén. Management will review the company’s interim financial results and provide an update on its business and pipeline developments. The presentation will be conducted in English.
Hansa Biopharma, listed on Nasdaq Stockholm as HNSA, is focused on developing novel enzyme․ based therapies for rare immunological diseases. The earnings call will provide investors and analysts with an update on the company's financial performance and strategic progress.
Presentation slides will be made available on the company's website following the release of the interim report. Interested parties are encouraged to join the call for the latest information.